BRPI1006692A2 - marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideo - Google Patents
marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideoInfo
- Publication number
- BRPI1006692A2 BRPI1006692A2 BRPI1006692A BRPI1006692A BRPI1006692A2 BR PI1006692 A2 BRPI1006692 A2 BR PI1006692A2 BR PI1006692 A BRPI1006692 A BR PI1006692A BR PI1006692 A BRPI1006692 A BR PI1006692A BR PI1006692 A2 BRPI1006692 A2 BR PI1006692A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnostic
- polypeptide
- cce
- ccr
- data acquisition
- Prior art date
Links
Classifications
-
- G01N33/57535—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Acoustics & Sound (AREA)
- High Energy & Nuclear Physics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09157464A EP2239577A1 (en) | 2009-04-07 | 2009-04-07 | Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma |
| PCT/IB2010/051395 WO2010119362A1 (en) | 2009-04-07 | 2010-03-31 | Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006692A2 true BRPI1006692A2 (pt) | 2016-04-12 |
Family
ID=40996843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006692A BRPI1006692A2 (pt) | 2009-04-07 | 2010-03-31 | marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideo |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120093734A1 (pt) |
| EP (2) | EP2239577A1 (pt) |
| CN (1) | CN102803967A (pt) |
| BR (1) | BRPI1006692A2 (pt) |
| RU (1) | RU2011144835A (pt) |
| WO (1) | WO2010119362A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2968562B1 (fr) * | 2010-12-14 | 2013-01-11 | Guerbet Sa | Composes pour le diagnostic de maladies liees a l'expression de muc5ac |
| WO2016203118A1 (en) * | 2015-06-18 | 2016-12-22 | Turun Yliopisto | Crystal structures of cip2a |
| EP3389693A4 (en) * | 2015-12-18 | 2019-08-21 | Agilvax, Inc. | COMPOSITIONS AND METHODS RELATED TO XCT PEPTIDES |
| CN106967789A (zh) * | 2017-01-26 | 2017-07-21 | 上海长海医院 | 一种前列腺癌标志物plxna1及其应用 |
| CN111194222A (zh) * | 2017-05-01 | 2020-05-22 | 阿吉尔瓦克斯公司 | 与xCT抗体相关的组合物和方法 |
| TW201905461A (zh) * | 2017-06-30 | 2019-02-01 | 國立研究開發法人醫藥基盤.健康.營養研究所 | 用以檢測大腸癌之生物標記 |
| WO2022063957A1 (en) * | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
| EP4279611A1 (en) * | 2022-05-17 | 2023-11-22 | Fundación Instituto de Estudios Ciencias de la Salud de Castilla y León (IECSCYL-IBSAL) | In vitro method for screening, diagnosis and/or prognosis of colorectal cancer |
| CN115851632B (zh) * | 2022-08-25 | 2024-04-26 | 华中农业大学 | 一种漆酶突变体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211149B1 (en) * | 1998-08-03 | 2001-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors of formation of protease resistant prion protein |
| WO2002057450A2 (en) * | 2000-11-29 | 2002-07-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US20040053824A1 (en) * | 2001-06-29 | 2004-03-18 | Tang Y Tom | Extracellular matrix and cell adhesion molecules |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US7488584B2 (en) * | 2006-03-24 | 2009-02-10 | Picobella | Methods for diagnosing and treating kidney and colorectal cancer |
| WO2007142347A1 (ja) * | 2006-06-05 | 2007-12-13 | Shimadzu Corporation | 腫瘍マーカー及び癌疾病の罹患の識別方法 |
| GB0611116D0 (en) * | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
| WO2008116178A2 (en) * | 2007-03-21 | 2008-09-25 | Vanderbilt University | Systems and methods for diagnosis and prognosis of colorectal cancer |
| CA2684024A1 (en) * | 2007-05-10 | 2008-11-20 | F. Hoffmann-La Roche Ag | Use of timp-1 as a marker for colorectal cancer |
| WO2009050691A2 (en) * | 2007-10-19 | 2009-04-23 | Rappaport Family Institute For Research In The Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
-
2009
- 2009-04-07 EP EP09157464A patent/EP2239577A1/en not_active Ceased
-
2010
- 2010-03-31 CN CN2010800251870A patent/CN102803967A/zh active Pending
- 2010-03-31 EP EP10712791.2A patent/EP2417457B1/en not_active Not-in-force
- 2010-03-31 RU RU2011144835/10A patent/RU2011144835A/ru not_active Application Discontinuation
- 2010-03-31 US US13/262,711 patent/US20120093734A1/en not_active Abandoned
- 2010-03-31 BR BRPI1006692A patent/BRPI1006692A2/pt not_active IP Right Cessation
- 2010-03-31 WO PCT/IB2010/051395 patent/WO2010119362A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20120093734A1 (en) | 2012-04-19 |
| WO2010119362A1 (en) | 2010-10-21 |
| EP2239577A1 (en) | 2010-10-13 |
| CN102803967A (zh) | 2012-11-28 |
| EP2417457B1 (en) | 2015-05-13 |
| RU2011144835A (ru) | 2013-05-20 |
| WO2010119362A8 (en) | 2011-11-10 |
| EP2417457A1 (en) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006692A2 (pt) | marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideo | |
| IL257330B (en) | Compositions, methods and kits for diagnosis of lung cancer | |
| IL254062B (en) | Kits containing ptk7 antibody and their use in the treatment, detection, diagnosis or monitoring of cancer | |
| BRPI0918555A2 (pt) | anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição. | |
| LTC2358756I2 (lt) | Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9 | |
| IL235261B (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| IL238335A0 (en) | Prognostic and diagnostic methods for ovarian cancer, and compositions and uses thereof for treating same | |
| FR2961087B1 (fr) | Outil de prelevement d'un echantillon de tissu animal. | |
| EP2919659A4 (en) | MULTIMODAL IMAGING SYSTEMS, SIDES AND METHODS | |
| BR112012003759A2 (pt) | "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer." | |
| PL2376537T3 (pl) | Ludzkie przeciwciała przeciwko ludzkiemu czynnikowi tkankowemu | |
| EP2593795A4 (en) | DIAGNOSIS FOR DARM CANCER | |
| BRPI0910206A2 (pt) | sistema de formação de imagem de tomografia computadorizada e método | |
| SI3017286T1 (sl) | Postopek, komplet in sistem za slikanje vzorca krvi | |
| WO2014116833A3 (en) | Compositions and methods for detecting neoplasia | |
| EP2281903A4 (en) | CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE | |
| BR112012026707A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado | |
| BRPI1006996A2 (pt) | composição, método e uso | |
| BRPI0813364A2 (pt) | Métodos de diagnóstico e tratamento de câncer. | |
| EP2988131A4 (en) | Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof | |
| BR112013002441A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer | |
| BR112014026873A2 (pt) | método cosmético, composição cosmética e uso. | |
| HK1220253A1 (zh) | 诊断前列腺癌症的方法 | |
| IL245766A0 (en) | Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |